Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's letrozole 2.5 mg
tablets to Novartis' Femara® 2.5 mg tablets following a single, oral 2.5 mg (1 x 2.5 mg) dose
administered under fasting conditions.